BofA Securities has updated its stance on Lamb Weston (NYSE: LW), raising the price target to $80 from $68, while maintaining a Neutral rating on the stock.
The adjustment comes in the wake of recent disclosures by activist investors JANA Partners and Continental Grain, revealing their respective stakes in the company. JANA Partners announced a 5% holding, while Continental Grain reported a stake of less than 1%.
The filings from both JANA and Continental Grain indicate plans to engage with the board and management of Lamb Weston to discuss several issues. These include addressing what they describe as a "litany of self-inflicted missteps" such as customer demand planning and retention, ERP system implementation, and capital spending on capacity expansion projects.
Also on the agenda are Lamb Weston's share repurchase strategy and execution, management compensation practices with an emphasis on returns on capital versus growth at any cost, and the initiation of a review of strategic alternatives, which could include the potential sale of the company.
The collaboration between JANA Partners and Continental Grain is noteworthy due to the latter's expertise in the agricultural industry. They are working with several individuals, including former Lamb Weston Executive Chairman Tim McLevish and current Simply Goods Food CEO Joe Scalzo.
BofA Securities' analyst cited Lamb Weston's underwhelming stock performance year-to-date as a factor that made the activist involvement less surprising. The new price target is based on a 17 times multiple of the company's projected CY25 earnings per share (EPS), which has been increased from the previous 14 times multiples.
In other recent news, Lamb Weston Holdings (NYSE:LW) Inc. has seen a flurry of activity. TD Cowen raised its price target for the company to $79.00 following the revelation of a significant investment by JANA Partners, as detailed in a recent SEC filing. JANA Partners, in collaboration with Continental Grain, has acquired a 5% stake in Lamb Weston and plans to engage with the company's Board of Directors to explore strategic alternatives.
JPMorgan (NYSE:JPM) has downgraded Lamb Weston's stock from Overweight to Neutral due to concerns over restaurant demand, demand forecasting, and supply-demand dynamics. In contrast, Barclays (LON:BARC) has increased its price target on Lamb Weston shares from $70.00 to $74.00, maintaining an Overweight rating. This adjustment reflects Barclays' confidence in Lamb Weston's capacity management measures.
Lamb Weston reported mixed Q1 results for fiscal year 2025. The company saw a slight 1% decline in total sales year-over-year, while exceeding sales expectations due to an improved volume and price mix. Adjusted EBITDA for the quarter was recorded at $290 million, a decrease from the previous year, primarily due to higher manufacturing costs and a product withdrawal.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Lamb Weston's financial position and market performance. The company's market capitalization stands at $11.15 billion, with a P/E ratio of 18.32, indicating a moderate valuation relative to earnings. Notably, Lamb Weston has demonstrated a strong commitment to shareholder returns, having raised its dividend for 8 consecutive years, as highlighted by an InvestingPro Tip.
In line with the article's mention of recent stock performance, InvestingPro data reveals a significant 19.53% price total return over the past month, suggesting a potential turnaround in investor sentiment. This recent uptick may be partly attributed to the activist investor involvement discussed in the article.
Another InvestingPro Tip points out that Lamb Weston's liquid assets exceed short-term obligations, indicating a solid financial position. This strength could provide the company with flexibility as it addresses the concerns raised by JANA Partners and Continental Grain.
For readers seeking a more comprehensive analysis, InvestingPro offers 6 additional tips on Lamb Weston, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.